Syntheses, Neural Protective Activities, and Inhibition of Glycogen Synthase

Kinase-3 of Substituted Quinolines
Major strategies for experimental disease-modifying therapies include targeting multiple sites in Aβ metabolism (Aβ synthesis, aggregation, deposition and clearance), targeting tauopathy (modulation of tau phosphorylation and inhibition of tau aggregation), regulating cholesterol homeostasis, anti-excitotoxicity, anti-inflammation and modulating calcium homeostasis, among others. [1] [2] [3] A number of compounds has shown efficacy in AD transgenic mouse models, [4] [5] [6] [7] [8] [9] [10] [11] [12] but their efficacy in AD patients remains uncertain.
Moreover, several drug candidates in clinical trials failed to show benefits. [1] [2] [3] In our pursuit of finding neural protective compounds for AD, we use MC65 cells protection assay as our primary screen for bioactive compounds, [13] [14] [15] and a class of quinolines containing various substituents ( Figure 1 ) were found to have submicromolar activities. MC65 cells assay generates few false positive results and identifies leads that penetrate cells and ameliorate A oligomer-induced toxicity. 13 Moreover, studies of the enzyme assay inhibition of glycogen synthase kinase-3 (GSK-3) revealed several quinoline molecules inhibited the enzyme in nanomolar ranges.
GSK-3 is abundant in neurons of the central nervous system and catalyzes the phosphorylation of tau proteins, which are overexpressed in AD brains. 16 Hyperphosphorylation of tau proteins in brain from imbalanced activity of GSK-3 results in neurofibrillary tangles and leads to cell death. [16] [17] [18] Moreover, the "dual pathway" hypothesis 19 suggests that GSK-3 affects both hyperphosphorylation of tau and elevation of A via the enhancement of enzymatic processing of APP. A dual effect of reduction of A toxicity and inhibition of GSK-3 may provide a greater beneficial effect than conventional GSK-3 inhibitors and anti-A molecules. 20 Herein, we reported the syntheses of quinolines 2 -16 ( Figure 1 ) and evaluation of their bioactivities along with our previously reported quinoline 1. From an initial screening of synthesized substituted quinoline compounds using MC65 cells, we found that compound 1 possesses strong neuronal cell protective activity (vide infra).
Hence, its analogs, quinolines 2 -16 possessing different heterocycle-or arene-appended methylamino moiety at C8, different C5 aryloxy moieties, no C5 aryloxy group, and C6 hydroxyl function, were synthesized. A reductive amination reaction was used to assemble compounds 2 -7 via the coupling of amine 17 21 and aldehydes 18 -23 with sodium cyanoborohydride in methanol in good to moderate yields (Scheme 1). Aldehydes 18 -22 were obtained from commercial sources while 23 was prepared as reported. 22 Compounds 2 -7 contain different heterocycle-or arene-appended methylamino functions at C8, which depart from that of compound 1. 
The C8 appended 3-aminopropylamine function of compound 1 was also modified by introducing a 3-amino-3-oxopropylamine moiety at C8, i.e., compound 8, or varied by a 2-furanylamide group, compound 9. Compound 8 was readily synthesized from a Michael addition reaction of amine 17 with acrylamide in acetonitrile in a sealed tube at 120 o C in a 57% yield, and amide 9 was prepared in a 75% yield from the acylation reaction of amine 17 with 2-furancarbonyl chloride (24) (Scheme 2). Among the tested quinolines using MC65 cell assays, compounds 1 and 3 appear to be the most active quinolines (vide infra), hence the C6-hydroxyl analog of 3 and molecules possessing different substituents at C5, i.e., compounds 10 -16, were examined. The C6-methyl ether group of 17 was removed with boron tribromide in dichloromethane, and the resulting quinoline 25 condensed with aldehyde 19 to give hydroxyl analog 10 in a 52% yield. C5-Aryloxy analogs of 1 such as compounds 11 and 13 were obtained from a sequence of reactions starting from bromide 26 (Scheme 3). 21 Hence, nucleophilic aromatic substitution reactions of bromide 26 with potassium 3-fluorophenoxide (27) and potassium phenoxide (28) separately in DMF gave aryl ether 29 and 30 in 65 and 80% yield, respectively (Scheme 3).
Removal of the acetyl protecting group of 29 and 30 with HCl in ethanol followed by ring closing reactions with 3-buten-2-one and arsenic acid in phosphoric acid provided quinolines 31
and 32 in 35 and 45% yield, respectively. Reduction of the nitro function of 31 and 32 separately with iron in acetic acid followed by alkylation of the resulting 8-aminoquinolines 33 and 34 with 3-iodopropylphthalimide, 21 and deprotection with hydrazine afforded 11 and 13, respectively.
Condensation of amines 33 and 34 separately with 4-hydroxybenzaldehyde and sodium cyanoborohyride furnished amines 12 and 14, respectively. MC65 cell line was used as a screen to search for neural protective compounds against cell death induced by oligomeric A peptides.
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On day three, the induction of SC gene (in the absence of tetracycline) in MC65 cells leads to the production of the C99 fragment of amyloid precursor protein and subsequently to A peptides from the proteolysis by -secretase, resulting in cell death. Compounds that protect cell from death likely possess anti-A property.
An addition of tetracycline, an antioxidant, to the media of MC65 cells suppresses the production of C99 fragment and cells survive. Consequently, toxicity of the compound to MC65 cells is determined. Hyperphosphorylation of tau proteins by GSK-3 leads to the formation of neurofibrillary tangles, [16] [17] [18] [19] [20] hence inhibition of GSK-3 by selected quinoline compounds was conducted in search of possible mechanism of action. Protein kinase C (PKC) mediates the function of other proteins in signal-transduction pathways of different cell types through the phosphorylation of hydroxyl functions of serine and threonine residues of these proteins. 26 In particular, phosphorylation of potent activators of transcription would increase oncogene expressions resulting in the promotion of cancer progression. 27 Therefore, the inhibition of PKC was also carried out. Table 2 show potent but nondiscriminating inhibitions with IC 50 values against GSK-3 and PKC of 38 and 33 nM. Compound 3 possesses strong neuronal cell protection and inhibitory activity against GSK-3, therefore, to examine whether 3 is suitable for future in vivo efficacy study, the distribution of 3 in various tissues and possible toxic effects in the locomotors and inhibition of liver enzymes activities in mice were carried out. The amounts of 3 in various tissues were quantified by following a reported procedure, 29 and results are summarized in Table 3 from an oral gavage administration each day of 5 mg/Kg body weight of CD1 mice of 3 (two untreated and four treated mice were used) for 75 days. The amounts of 3 in various organs and plasma remained in low concentrations after 75 days and appeared to accumulate in brain and pancreases in greater amounts than other tissues and plasma. Possible liver toxicity was examined by measuring enzymatic activities of liver transaminases, aspartate aminotransferase (AST) and alanine transaminase (ALT), biomarkers of toxicity. Mice were sacrificed on day 75 after daily oral administration of 3. Blood was collected from heart by using syringe containing heparin to prevent clotting. Plasma was separated immediately to prevent hemolysis by centrifugation at 10,000 x g for 5 minutes. The enzymatic activities of AST and ALT were determined using a commercially available kit (Pointe Scientific, Inc, Canton, MI, USA), according to manufacturer's instructions. To evaluate the toxicity of 3 upon chronic administration, ALT and AST enzyme activities were evaluated in the plasma of control and treated mice, and results are depicted in Figure 3 . No significant difference in the activities of ALT and AST was observed between control and treated mice suggesting that 3 is relatively safe for long-term use. In summary, a number of neural protective quinoline molecules were synthesized and evaluated in cells and enzyme assays. Compound 3 and its C6-hydroxyl analog 10 were the most potent molecules and they inhibit GSK-3 selectively in nanomolar concentrations.
Compound 3 distributed mainly to the brain and pancreases in mice after administration of 5 mg/Kg daily by oral route over 75 days and showed no apparent toxicity through the examination of locomotors activity and liver transaminases. Hence, the molecule appears to be safe for long-term study in AD mouse model. The synthetic procedure leading to this class of neural protective compound is general and further structural optimization is possible for future drug discovery and development.
